What is the mechanism of action of Crizanlizumab in reducing pain crises in sickle cell disease (SCD)?

Crizanlizumab is a monoclonal antibody medication that binds to P-selectin, inhibiting white blood cell-endothelial and platelet-endothelial interactions on the blood vessel wall.